Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-1 in Squamous Cell Carcinoma of the Lung
NCT04496674Phase 2Terminated
- Sponsor
- German Cancer Research Center
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CC-1 in lung squamous cell carcinoma (LSCC), sponsored by German Cancer Research Center. Started Feb 2022; status: terminated.
02
Drugs
CC-1
03
Conditions
lung squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on NCT04496674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04496674.